Literature DB >> 28097500

Update on Aspirin-Exacerbated Respiratory Disease.

Katharine M Woessner1.   

Abstract

Aspirin-exacerbated respiratory disease (AERD) is an acquired disease characterized by chronic eosinophilic airway inflammation with underlying dysregulation of arachidonic acid metabolism. The purpose of this paper is to review the latest developments in our understanding of the underlying pathophysiology including the role of eosinophils, mast cells, innate lymphoid cells (ILC2), and platelets. Clinical features such as respiratory reactions induced by alcohol, aggressive nasal polyposis, and anosmia will allow for earlier recognition of these patients in clinical practice. The current state of the art management of AERD will be addressed including the ongoing central role for aspirin desensitization and high-dose aspirin therapy.

Entities:  

Keywords:  Arachidonic acid; Aspirin desensitization; Aspirin-exacerbated respiratory disease (AERD); Prostaglandin D2; Prostaglandin E2

Mesh:

Substances:

Year:  2017        PMID: 28097500     DOI: 10.1007/s11882-017-0673-6

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.806


  58 in total

1.  Platelet-driven leukotriene C4-mediated airway inflammation in mice is aspirin-sensitive and depends on T prostanoid receptors.

Authors:  Tao Liu; Denise Garofalo; Chunli Feng; Juying Lai; Howard Katz; Tanya M Laidlaw; Joshua A Boyce
Journal:  J Immunol       Date:  2015-04-22       Impact factor: 5.422

2.  Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma.

Authors:  A S Cowburn; K Sladek; J Soja; L Adamek; E Nizankowska; A Szczeklik; B K Lam; J F Penrose; F K Austen; S T Holgate; A P Sampson
Journal:  J Clin Invest       Date:  1998-02-15       Impact factor: 14.808

3.  Prominent role of IFN-γ in patients with aspirin-exacerbated respiratory disease.

Authors:  John W Steinke; Lixia Liu; Phillip Huyett; Julie Negri; Spencer C Payne; Larry Borish
Journal:  J Allergy Clin Immunol       Date:  2013-06-24       Impact factor: 10.793

4.  Survey-Defined Patient Experiences With Aspirin-Exacerbated Respiratory Disease.

Authors:  Von Ta; Andrew A White
Journal:  J Allergy Clin Immunol Pract       Date:  2015-04-07

5.  Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper.

Authors:  Eric Macy; Jonathan A Bernstein; Mariana C Castells; Sandra M Gawchik; Tak H Lee; Russell A Settipane; Ronald A Simon; Jeffrey Wald; Katharine M Woessner
Journal:  Ann Allergy Asthma Immunol       Date:  2007-02       Impact factor: 6.347

6.  An economic analysis of aspirin desensitization in aspirin-exacerbated respiratory disease.

Authors:  Marcus Shaker; Ano Lobb; Pamela Jenkins; Daniel O'Rourke; Steve K Takemoto; Salil Sheth; Thomas Burroughs; Mark S Dykewicz
Journal:  J Allergy Clin Immunol       Date:  2007-08-22       Impact factor: 10.793

7.  Modulation by aspirin of nuclear phospho-signal transducer and activator of transcription 6 expression: Possible role in therapeutic benefit associated with aspirin desensitization.

Authors:  John W Steinke; Jeffrey A Culp; Elizabeth Kropf; Larry Borish
Journal:  J Allergy Clin Immunol       Date:  2009-09-19       Impact factor: 10.793

Review 8.  Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management.

Authors:  Andrew Szczeklik; Donald D Stevenson
Journal:  J Allergy Clin Immunol       Date:  2003-05       Impact factor: 10.793

9.  Impaired E Prostanoid2 Expression and Resistance to Prostaglandin E2 in Nasal Polyp Fibroblasts from Subjects with Aspirin-Exacerbated Respiratory Disease.

Authors:  Katherine N Cahill; Benjamin A Raby; Xiaobo Zhou; Feng Guo; Derek Thibault; Andreas Baccarelli; Hyang-Min Byun; Neil Bhattacharyya; John W Steinke; Joshua A Boyce; Tanya M Laidlaw
Journal:  Am J Respir Cell Mol Biol       Date:  2016-01       Impact factor: 6.914

10.  Low E-prostanoid 2 receptor levels and deficient induction of the IL-1β/IL-1 type I receptor/COX-2 pathway: Vicious circle in patients with aspirin-exacerbated respiratory disease.

Authors:  Liliana Machado-Carvalho; Margarita Martín; Rosa Torres; Marta Gabasa; Isam Alobid; Joaquim Mullol; Laura Pujols; Jordi Roca-Ferrer; Cesar Picado
Journal:  J Allergy Clin Immunol       Date:  2015-11-10       Impact factor: 10.793

View more
  6 in total

1.  Lipid regulation of group 2 innate lymphoid cell function: Moving beyond epithelial cytokines.

Authors:  Taylor A Doherty; David H Broide
Journal:  J Allergy Clin Immunol       Date:  2018-03-06       Impact factor: 10.793

Review 2.  Role of group 2 innate lymphocytes in aspirin-exacerbated respiratory disease pathogenesis.

Authors:  Andrew A White; Taylor A Doherty
Journal:  Am J Rhinol Allergy       Date:  2018-01-01       Impact factor: 2.467

3.  Cytokine and Lipid Mediator Regulation of Group 2 Innate Lymphoid Cells (ILC2s) in Human Allergic Airway Disease.

Authors:  Kellen Cavagnero; Taylor A Doherty
Journal:  J Cytokine Biol       Date:  2017-08-04

Review 4.  Prostaglandins and Their Receptors in Eosinophil Function and As Therapeutic Targets.

Authors:  Miriam Peinhaupt; Eva M Sturm; Akos Heinemann
Journal:  Front Med (Lausanne)       Date:  2017-07-19

Review 5.  Contribution of Host Defence Proteins and Peptides to Host-Microbiota Interactions in Chronic Inflammatory Lung Diseases.

Authors:  Anne M van der Does; Gimano D Amatngalim; Bart Keijser; Pieter S Hiemstra; Remi Villenave
Journal:  Vaccines (Basel)       Date:  2018-07-28

6.  Aspirin-exacerbated Respiratory Disease: A Syndrome of Mast Cell-mediated PgD2 Overproduction.

Authors:  Larry Borish
Journal:  Am J Respir Crit Care Med       Date:  2019-09-15       Impact factor: 21.405

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.